How does sequential therapy compare with standard triple first-line therapy for the eradication of Helicobacter pylori?

2017 ◽  
Keyword(s):  
Helicobacter Pylori ◽  
Sequential Therapy ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

EFFICACY OF MODIFIED BISMUTH QUADRUPLE THERAPY (RBMA) AS FIRST-LINE THERAPY FOR ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH CHRONIC GASTRITIS

2019 ◽  
pp. 28-32
Author(s):  
Van Huy Tran
Keyword(s):  
Helicobacter Pylori ◽  
Adverse Effects ◽  
Chronic Gastritis ◽  
Eradication Rate ◽  
High Rate ◽  
First Line ◽  
Helicobacter Pylori Eradication ◽  
Quadruple Therapy ◽  
First Line Therapy ◽  
Line Therapy

Background and aims: Efficacy with substitution of tetracycline with amoxicillin, an antibiotics having a very low resistance rate and a high tolerability, in bismuth quadruple therapy (BQT) have not been studied in Vietnam. Our study aimed to evaluate the efficacy and tolerability of modified BQT vs. standard BQT for first-line Helicobacter pylori eradication. Patients and methods: This is a randomized, prospective study. 120 patients with H.pylori positive-chronic gastritis were randomly divided into two groups. The RBMA group containing rabeprazole 20 mg, bismuth subsalicylic 524mg, metronidazole 500mg, amoxicillin 1000mg, all 2 times a day, for 14 days. The RBMT group received rabeprazole, bismuth subsalicylic, metronidazole and tetracycline. Evaluation for compliance and drug-related side effects were evaluated at the end of two weeks. 4-6 weeks after the end of treatment, the H.pylori eradication rate was determined by the C13urease breath test. Results: Eradication rate was not statistically significative different between the RBMA and the RBMT: 91.2%; 95% confidence interval, 78.2% - 96.7%) vs. 90%; 95% CI, 81.6% - 96.3%) by per-protocol analysis (p = 0.42) and 86.7% (95%CI, 75.84% - 93.09%) vs. 75% (95%CI, 62.1% - 85.3%) by intention-to-treat analysis (ITT, p = 0.06). Adverse effects were significant higher in the RBMT group than in the RBMA group (48.3% vs. 26.7%; p = 0.071) and rate of good compliance was significantly higher in RBMA group than in RBMT group (p < 0.05). Conclusion: The modified BQT including rabeprazole, bismuth, metronidazole and amoxicillin achieved a fairly high rate of H.pylori infection eradication with a higher compliance and lower rate of adverse effects compared to the BQT in patients with chronic gastritis. Further studies need to conduct to confirm this new regimens as a first-line therapy in our country. Key words: Modified bismuth quadruple therapy, BQT, Helicobacter pylori eradication

scholarly journals Additive Effect of Pronase on the Eradication Rate of First-Line Therapy for Helicobacter pylori Infection

Gut and Liver ◽  
2015 ◽  
Vol 9 (3) ◽  
Author(s):  
Chang Seok Bang ◽  
Yeon Soo Kim ◽  
Sang Hyun Park ◽  
Jin Bong Kim ◽  
Gwang Ho Baik ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Eradication Rate ◽  
Helicobacter Pylori Infection ◽  
Additive Effect ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

Modified bismuth quadruple therapy with low‐dose metronidazole as first‐line therapy for Helicobacter pylori infection

Helicobacter ◽  
2020 ◽  
Author(s):  
Gyu Young Pih ◽  
Kee Don Choi ◽  
Eun Jeong Gong ◽  
Hee Kyong Na ◽  
Ji Yong Ahn ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Low Dose ◽  
Helicobacter Pylori Infection ◽  
First Line ◽  
Quadruple Therapy ◽  
First Line Therapy ◽  
Line Therapy

Quadruple concomitant non-bismuth therapy vs. classical triple therapy as first line therapy for Helicobacter pylori infection

2016 ◽  
Vol 147 (5) ◽  
pp. 199-201
Author(s):  
Ana Campillo ◽  
Miriam Ostiz ◽  
Edurne Amorena ◽  
Marcos Kutz ◽  
Matilde La Iglesia
Keyword(s):  
Helicobacter Pylori ◽  
Triple Therapy ◽  
Helicobacter Pylori Infection ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

Tu1329 Comparing the Efficacy among Concomitant, Sequential, and Tailored Therapy as the First-Line Therapy for Helicobacter pylori Eradication

2016 ◽  
Vol 150 (4) ◽  
pp. S876 ◽  
Author(s):  
Jin Il Kim ◽  
Dae Young Cheung ◽  
Jae J. Kim ◽  
Sang Woo Lee
Keyword(s):  
Helicobacter Pylori ◽  
First Line ◽  
Tailored Therapy ◽  
Helicobacter Pylori Eradication ◽  
First Line Therapy ◽  
Line Therapy

Comparison of Levofloxacin- and Moxifloxacin-Based Triple Therapies with Standard Treatment in Eradication of Helicobacter Pylori as First-Line Therapy

Digestion ◽  
2014 ◽  
Vol 90 (4) ◽  
pp. 261-264 ◽  
Author(s):  
Halil Rakici ◽  
Teslime Ayaz ◽  
Remzi Adnan Akdogan ◽  
Recep Bedir
Keyword(s):  
Helicobacter Pylori ◽  
Standard Treatment ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

Camrelizumab combined with capecitabine and oxaliplatin followed by camrelizumab and apatinib as first-line therapy for advanced or metastatic gastric or gastroesophageal junction cancer: Updated results from a multicenter, open label phase II trial.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 4031-4031 ◽  
Author(s):  
Lin Shen ◽  
Zhi Peng ◽  
Yan-Qiao Zhang ◽  
Jia Wei ◽  
Feng Wang ◽  
...  
Keyword(s):  
Gastroesophageal Junction ◽  
Objective Response ◽  
Progression Free Survival ◽  
Sequential Therapy ◽  
Metastatic Gastric Cancer ◽  
First Line ◽  
Open Label ◽  
First Line Therapy ◽  
Line Therapy ◽  
Open Label Phase

4031 Background: Capecitabine plus oxaliplatin (CAPOX) is one of the standard first-line treatments for advanced or metastatic gastric cancer. Camrelizumab (SHR-1210, an anti–PD-1 antibody) shows promising anti-tumor activity in patients (pts) with advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer. Camrelizumab combined with CAPOX for untreated G/GEJ cancer was assessed as a part of an ongoing multicenter, open-label phase 2 trial (cohort 1), and encouraging preliminary results were reported. Here, we present the updated safety and efficacy data. Methods: In this cohort, systemic treatment naïve pts with HER2– advanced or metastatic G/GEJ adenocarcinoma were given camrelizumab 200 mg on Day 1, capecitabine 1000 mg/m2 bid on Days 1–14 and oxaliplatin 130 mg/m2 on Day 1 of each 21-day-cycle for 4 to 6 cycles followed by camrelizumab 200 mg every 3 weeks plus apatinib 375 mg qd until disease progression or intolerable toxicity. The primary endpoint was objective response rate. Results: At data cutoff (Jan 20, 2019), 43 of the 48 enrolled pts were evaluable. Partial response was observed in 28 pts (65%), and 19 (44%) were confirmed. Stable disease in 14 pts and progressive disease in 10 pts were reported. Median estimates for duration of response and progression-free survival were not reached. Grade ≥3 treatment-related adverse events (TRAEs) occurred in 9 pts (21%), included neutropenia, diarrhea, rash and elevated ALT, whereas none of the TRAEs was fatal. Ten pts without progression after 4–6 cycles of camrelizumab and CAPOX combination therapy all received camrelizumab plus apatinib as sequential therapy, and no new safety signals were observed. Conclusions: The updated results confirmed that camrelizumab plus CAPOX followed by camrelizumab plus apatinib was well tolerated with noteworthy responses as first-line therapy in advanced or metastatic G/GEJ cancer pts. Expansion of this cohort in a phase 3 study are under way. Clinical trial information: NCT03472365.

Sign in / Sign up

Export Citation Format

Share Document